Page last updated: 2024-11-06

n-acetyltryptamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetyltryptamine (NAT) is a naturally occurring tryptamine derivative found in various plants and animals. It is a potent agonist of the 5-HT1A receptor, which is involved in regulating mood, anxiety, and sleep. NAT is also known to have anticonvulsant and analgesic properties. Research on NAT is ongoing, with a focus on its potential therapeutic applications in the treatment of depression, anxiety, and other neurological disorders. Studies have investigated its synthesis, effects, and pharmacological properties, exploring its role in various physiological processes and potential therapeutic uses.'

N-acetyltryptamine: antagonizes the melatonin-induced inhibition of dopamine release from retina; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetyltryptamine : A tryptamine compound having an acetyl substituent attached to the side-chain amino function. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70547
CHEMBL ID33171
CHEBI ID55515
SCHEMBL ID468850
MeSH IDM0127909

Synonyms (89)

Synonym
EU-0033445
MLS002153204
HMS3266I05
STL352108
LOPAC0_000101
EU-0100101
n-acetyltryptamine, powder
NCGC00015088-01
tocris-0357
NCGC00024552-01
lopac-a-7342
ACON1_000465
PDSP2_001798
PDSP1_001815
ISUPSL100255
acetamide, n-(2-indol-3-ylethyl)- (7ci,8ci)
acetotryptamide n-acetyl-2-(indol-3-yl)ethylamine
acetamide, n-[2-(1h-indol-3-yl)ethyl]-
1016-47-3
acetamide, n-(2-(1h-indol-3-yl)ethyl)-
acetamide, n-[2-(1h-indol-3-yl)ethyl]- (9ci)
3-(2-n-acetylaminoethyl)indole
NCGC00024552-04
NCGC00024552-05
NCGC00024552-06
NCGC00024552-02
NCGC00024552-03
n-acetyltryptamine
smr000686036
MLS001250169
n-(2-(1h-indol-3-yl)ethyl)acetamide
NCGC00015088-03
A 7342
n-[2-(1h-indol-3-yl)-ethyl]-acetamide
NCGC00015088-08
CHEMBL33171 ,
chebi:55515 ,
AKOS000639631
n-[2-(1h-indol-3-yl)ethyl]acetamide
bdbm50282758
HMS3260E04
CCG-204196
HMS2270O21
NCGC00015088-02
NCGC00015088-06
NCGC00015088-05
NCGC00015088-04
NCGC00015088-07
LP00101
NCGC00260786-01
tox21_500101
SCHEMBL468850
acetamide, n-(2-indol-3-ylethyl)-
acetotryptamide
n-[2-(1h-indol-3-yl)ethyl]acetamide #
3-(2-acetamidoethyl)indole
n-acetyltryptamine; n10-acetyltryptamine; nb-acetyltryptamine; nomega-acetyltryptamine
DTXSID30144042
mfcd00209910
J-000457
7an ,
AS-63601
SR-01000075685-2
SR-01000075685-1
sr-01000075685
SR-01000075685-4
NCGC00015088-09
ncgc00015088-09_c12h14n2o_n-[2-(1h-indol-3-yl)ethyl]acetamide
374572-55-1
Z26395416
2-(n,n-dimethyliminium)-4-ethyl-5-mercapto-1,3-dithiol,innersalt
HMS3675G05
Q27124335
HMS3411G05
BRD-K73700643-001-04-7
BRD-K73700643-001-10-4
SDCCGSBI-0050089.P002
N17090
nb-acetyltryptamine
acetyltryptamine, n-
n-acetyltryptamine; n10-acetyltryptamine; nb-acetyltryptamine; n-acetyltryptamine
BAA01647
CS-0020578
HY-100908
acetamide,n-[2-(1h-indol-3-yl)ethyl]-
EN300-189721
n-acetyl-d3-tryptamine
AKOS040759465
SY055334

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.23350.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.22390.044717.8581100.0000AID485294
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID2323
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.18890.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency1.67890.000811.382244.6684AID686978
Smad3Homo sapiens (human)Potency8.91250.00527.809829.0929AID588855
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00450.540617.639296.1227AID2364; AID2528
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
chromobox protein homolog 1Homo sapiens (human)Potency26.67950.006026.168889.1251AID488953
flap endonuclease 1Homo sapiens (human)Potency33.58750.133725.412989.1251AID588795
gemininHomo sapiens (human)Potency0.65130.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency5.62340.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency2.51192.511912.262825.1189AID954; AID958
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency33.80780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Melatonin receptor type 1AGallus gallus (chicken)Ki0.48980.00000.16870.8700AID107546
Melatonin receptor type 1CGallus gallus (chicken)Ki0.48980.00000.16870.8700AID107546
Melatonin receptor type 1BGallus gallus (chicken)Ki0.48980.00000.16170.8700AID107546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayMelatonin receptor type 1AGallus gallus (chicken)
negative regulation of glycolytic processMelatonin receptor type 1AGallus gallus (chicken)
negative regulation of glucose importMelatonin receptor type 1AGallus gallus (chicken)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1AGallus gallus (chicken)
negative regulation of glycolytic processMelatonin receptor type 1CGallus gallus (chicken)
negative regulation of glucose importMelatonin receptor type 1CGallus gallus (chicken)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1CGallus gallus (chicken)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1BGallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
melatonin receptor activityMelatonin receptor type 1AGallus gallus (chicken)
hormone bindingMelatonin receptor type 1AGallus gallus (chicken)
melatonin bindingMelatonin receptor type 1AGallus gallus (chicken)
G protein-coupled receptor activityMelatonin receptor type 1AGallus gallus (chicken)
melatonin receptor activityMelatonin receptor type 1CGallus gallus (chicken)
melatonin bindingMelatonin receptor type 1CGallus gallus (chicken)
G protein-coupled receptor activityMelatonin receptor type 1CGallus gallus (chicken)
melatonin receptor activityMelatonin receptor type 1BGallus gallus (chicken)
G protein-coupled receptor activityMelatonin receptor type 1BGallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
receptor complexMelatonin receptor type 1AGallus gallus (chicken)
plasma membraneMelatonin receptor type 1AGallus gallus (chicken)
nucleoplasmMelatonin receptor type 1CGallus gallus (chicken)
plasma membraneMelatonin receptor type 1CGallus gallus (chicken)
plasma membraneMelatonin receptor type 1BGallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1127072Antiplasmodial activity against Plasmodium falciparum 3D7 infected in erythrocytes assessed as parasitemia level at 500 nM after 48 hrs by YOYO-1 staining-based flow cytometry relative to control2014European journal of medicinal chemistry, May-06, Volume: 78Synthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite Plasmodium falciparum.
AID1082989Antifungal activity against Leptosphaeria maculans isolate BJ-125/UAMH-9410 assessed as mycelial growth inhibition at 0.2 mM incubated under constant light for 5 days by mycelial radial growth bioassay2012Journal of agricultural and food chemistry, Aug-15, Volume: 60, Issue:32
Metabolism and metabolites of dithiocarbamates in the plant pathogenic fungus Leptosphaeria maculans.
AID1127074Antiplasmodial activity against asynchronous culture of Plasmodium falciparum 3D7 infected in erythrocytes assessed as reduction of melatonin-induced increase in parasitemia level at 500 nM after 48 hrs by YOYO-1 staining-based flow cytometry (Rvb = 23.5 2014European journal of medicinal chemistry, May-06, Volume: 78Synthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite Plasmodium falciparum.
AID1134000Inhibition of chymotrypsin (unknown origin)1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Quantitative structure-activity relationships of chymotrypsin. On the predictive value of correlation equations.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1082988Antifungal activity against Leptosphaeria maculans isolate BJ-125/UAMH-9410 assessed as mycelial growth inhibition at 0.1 mM incubated under constant light for 5 days by mycelial radial growth bioassay2012Journal of agricultural and food chemistry, Aug-15, Volume: 60, Issue:32
Metabolism and metabolites of dithiocarbamates in the plant pathogenic fungus Leptosphaeria maculans.
AID1082990Antifungal activity against Leptosphaeria maculans isolate BJ-125/UAMH-9410 assessed as mycelial growth inhibition at 0.5 mM incubated under constant light for 5 days by mycelial radial growth bioassay2012Journal of agricultural and food chemistry, Aug-15, Volume: 60, Issue:32
Metabolism and metabolites of dithiocarbamates in the plant pathogenic fungus Leptosphaeria maculans.
AID107400Negative logarithm of relative affinity (pRA) towards melatonin receptor (relative to N-acetyl-5-methoxytryptamine (aMT))1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
AID107876Relative Intrinsic activity evaluated on [35S]GTP-gamma-S, binding in NIH3T3 cells stably transfected with human Melatonin receptor type 1A2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
AID108040Relative Intrinsic activity evaluated on [35S]GTP-gamma-S, binding in NIH3T3 cells stably transfected with human Melatonin receptor type 1B2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
AID107546Binding affinity against chicken brain melatonin receptors using 2-[125I]iodomelatonin as radioligand1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (7.84)18.7374
1990's9 (17.65)18.2507
2000's13 (25.49)29.6817
2010's16 (31.37)24.3611
2020's9 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.68 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index23.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]